Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label dose-escalation and expansion study of SAR443579 in relapsed or refractory CD123-positive hematologic malignancies
CTR20241009Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Apr 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SAR443579 in acute myeloid leukemia (AML), B cell acute lymphoblastic leukemia (B-ALL), myelodysplastic syndrome (MDS), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by Sanofi. Started Apr 2024; status: terminated.
02
Drugs
SAR443579
03
Conditions
acute myeloid leukemia (AML)B cell acute lymphoblastic leukemia (B-ALL)myelodysplastic syndrome (MDS)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on CTR20241009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241009.